$29.96
0.44% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US19459J1043
Symbol
COLL

Collegium Pharmaceutical, Inc. Stock price

$29.96
+3.05 11.33% 1M
-0.04 0.13% 6M
+1.31 4.57% YTD
-4.19 12.27% 1Y
+13.60 83.13% 3Y
+7.91 35.87% 5Y
+13.28 79.62% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.13 0.44%
ISIN
US19459J1043
Symbol
COLL
Sector
Industry

Key metrics

Market capitalization $962.98m
Enterprise Value $1.71b
P/E (TTM) P/E ratio 24.69
EV/FCF (TTM) EV/FCF 8.71
EV/Sales (TTM) EV/Sales 2.58
P/S ratio (TTM) P/S ratio 1.45
P/B ratio (TTM) P/B ratio 4.11
Revenue growth (TTM) Revenue growth 17.17%
Revenue (TTM) Revenue $664.28m
EBIT (operating result TTM) EBIT $165.42m
Free Cash Flow (TTM) Free Cash Flow $196.56m
Cash position $217.63m
EPS (TTM) EPS $1.21
P/E forward 16.58
P/S forward 1.29
EV/Sales forward 2.30
Short interest 16.93%
Show more

Is Collegium Pharmaceutical, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Collegium Pharmaceutical, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Collegium Pharmaceutical, Inc. forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a Collegium Pharmaceutical, Inc. forecast:

Buy
80%
Hold
20%

Financial data from Collegium Pharmaceutical, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
664 664
17% 17%
100%
- Direct Costs 281 281
24% 24%
42%
383 383
13% 13%
58%
- Selling and Administrative Expenses 28 28
1,173% 1,173%
4%
- Research and Development Expense - -
-
-
356 356
5% 5%
54%
- Depreciation and Amortization 190 190
30% 30%
29%
EBIT (Operating Income) EBIT 165 165
14% 14%
25%
Net Profit 44 44
53% 53%
7%

In millions USD.

Don't miss a Thing! We will send you all news about Collegium Pharmaceutical, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Collegium Pharmaceutical, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:
Neutral
GlobeNewsWire
9 days ago
STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company's common stock. ...
Neutral
Seeking Alpha
12 days ago
Call Start: 16:30 January 1, 0000 5:05 PM ET Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q1 2025 Earnings Call May 8, 2025 16:30 ET Company Participants Ian Karp - Head, Investor Relations Vikram Karnani - President and Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants Les Sulewski - Truist Securities Serge Be...
More Collegium Pharmaceutical, Inc. News

Company Profile

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.

Head office United States
CEO Vikram Karnani
Employees 357
Founded 2002
Website www.collegiumpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today